JP2023543137A5 - - Google Patents
Info
- Publication number
- JP2023543137A5 JP2023543137A5 JP2023514105A JP2023514105A JP2023543137A5 JP 2023543137 A5 JP2023543137 A5 JP 2023543137A5 JP 2023514105 A JP2023514105 A JP 2023514105A JP 2023514105 A JP2023514105 A JP 2023514105A JP 2023543137 A5 JP2023543137 A5 JP 2023543137A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063072080P | 2020-08-28 | 2020-08-28 | |
| US63/072,080 | 2020-08-28 | ||
| PCT/US2021/048066 WO2022047237A1 (en) | 2020-08-28 | 2021-08-27 | Engineered immune cells with priming receptors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023543137A JP2023543137A (ja) | 2023-10-13 |
| JP2023543137A5 true JP2023543137A5 (https=) | 2024-09-03 |
| JPWO2022047237A5 JPWO2022047237A5 (https=) | 2024-09-03 |
Family
ID=80352430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023514105A Withdrawn JP2023543137A (ja) | 2020-08-28 | 2021-08-27 | プライミング受容体で操作された免疫細胞 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230340409A1 (https=) |
| EP (1) | EP4204575A4 (https=) |
| JP (1) | JP2023543137A (https=) |
| KR (1) | KR20230083275A (https=) |
| CN (1) | CN116529364A (https=) |
| AU (1) | AU2021334366A1 (https=) |
| CA (1) | CA3191148A1 (https=) |
| IL (1) | IL300994A (https=) |
| MX (1) | MX2023002455A (https=) |
| WO (1) | WO2022047237A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL302315A (en) * | 2020-10-26 | 2023-06-01 | Arsenal Biosciences Inc | Secure port sites |
| EP4496806A2 (en) * | 2022-04-20 | 2025-01-29 | Arsenal Biosciences, Inc. | Cells comprising a suppressor of gene expression and/or a synthetic pathway activator and/or an inducible payload |
| AU2023272589A1 (en) * | 2022-05-17 | 2025-01-09 | Arsenal Biosciences, Inc. | Systems of engineered receptors targeting psma and ca9 |
| KR20250158048A (ko) | 2023-03-03 | 2025-11-05 | 아스널 바이오사이언시스, 인크. | Psma 및 ca9을 표적으로 하는 시스템 |
| PE20252678A1 (es) * | 2023-03-13 | 2025-11-24 | Arsenal Biosciences Inc | Activadores de vias sinteticas |
| CN121674486A (zh) * | 2026-02-10 | 2026-03-17 | 潍坊吉涛医学科技有限公司 | 基于慢病毒载体的羊膜细胞永生化建系方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018175636A2 (en) * | 2017-03-22 | 2018-09-27 | Novartis Ag | Compositions and methods for immunooncology |
| MX2020004541A (es) * | 2017-10-30 | 2021-04-12 | Pact Pharma Inc | Edicion de genes de celulas primarias. |
| EP3796894A4 (en) * | 2018-04-24 | 2022-05-04 | Ligandal, Inc. | METHODS AND COMPOSITIONS FOR GENOMIC EDITING |
| CN110184301B (zh) * | 2018-04-28 | 2023-02-24 | 辉大(上海)生物科技有限公司 | 通过Tild-CRISPR实现高效精确的靶向整合 |
| AU2020355025A1 (en) * | 2019-09-23 | 2022-04-07 | Regents Of The University Of Minnesota | Genetically-edited immune cells and methods of therapy |
| IL302315A (en) * | 2020-10-26 | 2023-06-01 | Arsenal Biosciences Inc | Secure port sites |
| JP2024512608A (ja) * | 2021-03-24 | 2024-03-19 | ジェネンテック， インコーポレイテッド | Ｔリンパ球における効率的なｔｃｒ遺伝子編集 |
| CA3227759A1 (en) * | 2021-08-11 | 2023-02-16 | Sebastien Levesque | Mtor-targeted modification and uses thereof |
-
2021
- 2021-08-27 AU AU2021334366A patent/AU2021334366A1/en active Pending
- 2021-08-27 MX MX2023002455A patent/MX2023002455A/es unknown
- 2021-08-27 CA CA3191148A patent/CA3191148A1/en active Pending
- 2021-08-27 IL IL300994A patent/IL300994A/en unknown
- 2021-08-27 KR KR1020237010538A patent/KR20230083275A/ko active Pending
- 2021-08-27 CN CN202180073716.2A patent/CN116529364A/zh active Pending
- 2021-08-27 EP EP21862873.3A patent/EP4204575A4/en not_active Withdrawn
- 2021-08-27 WO PCT/US2021/048066 patent/WO2022047237A1/en not_active Ceased
- 2021-08-27 JP JP2023514105A patent/JP2023543137A/ja not_active Withdrawn
-
2023
- 2023-02-27 US US18/114,981 patent/US20230340409A1/en active Pending